tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Andreas Argyrides, 97 are a BUY (81.51%), 17 are a HOLD (14.29%), 5 are a SELL (4.2%).
Analyst Andreas Argyrides, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 33.94% that have a potential upside of 50.5% achieved within 125 days. Previously, Andreas Argyrides worked at WEDBUSH.
Andreas Argyrides’s has documented 235 price targets and ratings displayed on 30 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on KROS, Keros Therapeutics at 12-Nov-2025.
Analyst best performing recommendations are on MNPR (MONOPAR THERAPEUTICS).
The best stock recommendation documented was for MNPR (MONOPAR THERAPEUTICS) at 9/3/2025. The price target of $77 was fulfilled within 22 days with a profit of $40.79 (112.65%) receiving and performance score of 51.2.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$52
$38.61 (288.35%)
27 days ago
(20-Nov-2025)
0/7 (0%)
$41.13 (378.38%)
Buy
$19
$5.61 (41.90%)
$25
1 months 10 days ago
(07-Nov-2025)
4/15 (26.67%)
$7.79 (69.49%)
50
Buy
$34
$20.61 (153.92%)
$34
3 months 9 days ago
(08-Sep-2025)
0/11 (0%)
$24.52 (258.65%)
Hold
$12
$-1.39 (-10.38%)
$14
8 months ago
(17-Apr-2025)
1/3 (33.33%)
$6.06 (102.02%)
174
Buy
$24
$10.61 (79.24%)
$22
9 months 3 days ago
(14-Mar-2025)
0/2 (0%)
$17.28 (257.14%)
Which stock is Andreas Argyrides is most bullish on?
Which stock is Andreas Argyrides is most reserved on?
What Year was the first public recommendation made by Andreas Argyrides?
